FIELD: medicine.
SUBSTANCE: immunophenotyping of blood lymphocytes taken from the ulnar vein prior to surgery, as well as lymphocytes of the tumor tissue and the peritumoral region is performed to identify subpopulations of lymphocytes, such as αβCr - T-lymphocytes with a receptor αβ in the blood (X1), CD4+Peri - T-helper-inductor lymphocytes in the peritumoral zone (X2), CD8+Peri - cytotoxic T-lymphocytes in the peritumoral zone (X3), CD19+Peri - B-lymphocytes in the peritumoral zone (X4), CD19+tum - B-lymphocytes in the tumor zone (X5), then the risk of metastasis of locally advanced colon cancer Rm is determined by the formula and with Rm value of 0.5 or more, metastases of locally advanced colon cancer are predicted for the next 2 years, with Rm value of less than 0.5, no risk is predicted.
EFFECT: method allows to timely and individually predict the development of metastases of locally advanced colon cancer in the next 2 years.
2 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-EGFR THERAPY | 2024 |
|
RU2820402C1 |
METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF POSTOPERATIVE CARDIOVASCULAR COMPLICATIONS OF LAPAROSCOPIC OPERATIONS IN METASTATIC COLON CANCER | 2017 |
|
RU2663078C1 |
METHOD FOR INDIVIDUAL PREDICTION OF PROGRESSION OF SQUAMOUS CELL ESOPHAGUS CANCER II-III STAGE AFTER SURGICAL TREATMENT | 2019 |
|
RU2712921C1 |
METHOD FOR PREDICTION OF ESOPHAGEAL CANCER PROGRESSION | 2016 |
|
RU2640954C1 |
METHOD OF TREATING ONCOLOGICAL DISEASES | 2020 |
|
RU2741701C1 |
METHOD OF ADJUVANT IMMUNOTHERAPY OF PRIMARY AND METASTATIC MALIGNANT UNRESECTABLE LIVER TUMOURS | 2006 |
|
RU2326601C2 |
METHOD OF PREDICTING LYMPHOGENOUS METASTASIS OF COLON CANCER | 2022 |
|
RU2800534C1 |
METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
METHOD FOR PREDICTION OF EFFECTIVENESS OF CONSERVATIVE TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2023 |
|
RU2817324C1 |
METHOD FOR ASSESSING RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-VEGF THERAPY | 2024 |
|
RU2823505C1 |
Authors
Dates
2017-05-15—Published
2016-02-11—Filed